Moreover, EZH2 is often upregulated in various cancers and the expression of EZH2 often correlates with poor patient outcome (Chase and Cross, 2011; Chen et al., 2015); although this could, at least in some cases, be simply reflecting the higher proliferative phenotype associated with cancer progression (Wassef et al., 2015). Here, EZH2 is linked to cancer.